STOCK TITAN

Evaxion Biotech A/S - EVAX STOCK NEWS

Welcome to our dedicated news page for Evaxion Biotech A/S (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evaxion Biotech A/S's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evaxion Biotech A/S's position in the market.

Rhea-AI Summary
Evaxion Biotech receives notification letter from Nasdaq regarding bid price deficiency
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Evaxion Biotech announces collaboration with Afrigen Biologics for the development of a gonorrhea vaccine based on Evaxion's EDEN™ platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.67%
Tags
partnership
-
Rhea-AI Summary
Evaxion announces collaboration for AI-designed vaccine candidate against undisclosed bacterial pathogen
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.48%
Tags
none
Rhea-AI Summary
Evaxion achieves groundbreaking milestone in vaccine discovery with AI-powered platform EDENTM
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.52%
Tags
AI
-
Rhea-AI Summary
Evaxion Biotech announces appointment of new CEO to accelerate strategic development and execution of business opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
management AI
-
Rhea-AI Summary
Evaxion Biotech provides business update and financial results for Q2 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) Announces Up to $20 Million Financing Agreement with Negma Group Investment Ltd to Advance Cancer Vaccine EVX-03
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
Evaxion Biotech A/S

Nasdaq:EVAX

EVAX Rankings

EVAX Stock Data

21.38M
36.13M
16.6%
0.93%
0.82%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Denmark
Horsholm

About EVAX

since 2008, evaxion biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence, with the mission to solve some of the world’s most significant challenges to human health. evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, pioneer and eden. using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. eden enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while pioneer has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them. to learn more about evaxion, please visit http://www.evaxion-biotech.ai